Advanced Medical Solutions Group plc, an AIM-quoted company and constituent of the FTSE AIM All Share Index, appears to be in an offer period. Its regulatory news feed on 4 November 2026 was dominated by Takeover Code filings, including a Rule 2.9 announcement and a string of Form 8.3 and Form 8.5 dealing disclosures.

The Rule 2.9 announcement, published at 1:42 p.m. on 4 November, stated that the company had 221,042,797 ordinary shares of 5p each in issue and admitted to trading on AIM, with none held in treasury, so all carry voting rights. The summary of the announcement did not name any offeror or give offer terms, and the identity of any bidder could not be confirmed. Readers should read the original notice for the full position.

What the filings show

A Rule 2.9 notice is normally released when an Offer Period starts, and it reminds holders of 1% or more of the company's shares of their duty to disclose positions and dealings. One Form 8.3 filed on 4 November 2026 reported that Glazer Capital, LLC held 8,404,454 ordinary shares, or 3.80%, as at 3 November 2026, and had bought 79,540 shares at £2.83 each. That form did not identify the offer to which it related.

The listing also showed Form 8.3 filings on 3 November 2026 and a holdings notice on 4 November. These disclosures are mandatory for parties above the threshold, and they indicate market activity in the shares, not the terms of any proposal.

Why identity cannot be confirmed

Because the announcement texts read did not name a bidder, this article does not state that a takeover offer has been made, or by whom. The pattern is consistent with an offer period, but the nature of the approach, its price and its status remain unconfirmed. No trading update, results or Dividend information was reviewed, and no description of the group's operations was confirmed from the sources used.

Sector and index context

Advanced Medical Solutions is quoted on AIM and forms part of the FTSE AIM All Share Index, although no share price or index weighting was confirmed. The only price point found was the £2.83 purchase price reported in the Glazer Capital filing, which relates to a single trade on 3 November 2026 and should not be taken as a market quotation. Offer periods on AIM can attract Merger arbitrage funds, which often file such disclosures when they build positions.

Risks and what to watch

In practice, the Takeover Code is designed to ensure that all shareholders are treated equally and receive information at the same time, which is why so many disclosures appear during an offer period.

An offer period brings uncertainty. A possible approach may lapse, the terms may change, or a board may reject it. Shareholders would normally look for a statement from the company confirming whether an approach has been received, the identity of the interested party, and a deadline by which a firm offer must be announced or withdrawn.

Readers should watch for any such statement, further Rule 2.9 or Rule 2.4 announcements, continuing Form 8 disclosures and the company's usual financial reporting timetable. Anyone relying on the figures here should check them against the original RNS announcements, as the details above came from summarised pages.

Until the company or a counterparty makes a clearer statement, the position described here should be regarded as provisional.